A detailed history of State Street Corp transactions in Nuvation Bio Inc. stock. As of the latest transaction made, State Street Corp holds 3,043,510 shares of NUVB stock, worth $8.89 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,043,510
Previous 3,062,214 0.61%
Holding current value
$8.89 Million
Previous $4.62 Million 139.63%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$1.46 - $3.97 $27,307 - $74,254
-18,704 Reduced 0.61%
3,043,510 $11.1 Million
Q4 2023

Feb 14, 2024

BUY
$0.96 - $1.53 $31,746 - $50,595
33,069 Added 1.09%
3,062,214 $4.62 Million
Q3 2023

Nov 14, 2023

BUY
$1.26 - $2.1 $9,700 - $16,167
7,699 Added 0.25%
3,029,145 $4.06 Million
Q2 2023

Aug 14, 2023

BUY
$1.56 - $1.84 $355,740 - $419,591
228,039 Added 8.16%
3,021,446 $5.44 Million
Q1 2023

May 15, 2023

BUY
$1.6 - $2.48 $217,112 - $336,523
135,695 Added 5.11%
2,793,407 $4.64 Million
Q4 2022

Feb 14, 2023

SELL
$1.68 - $2.5 $693,312 - $1.03 Million
-412,686 Reduced 13.44%
2,657,712 $5.1 Million
Q3 2022

Nov 15, 2022

BUY
$0.29 - $4.04 $35,462 - $494,027
122,284 Added 4.15%
3,070,398 $6.88 Million
Q2 2022

Aug 15, 2022

SELL
$3.24 - $5.85 $157,894 - $285,088
-48,733 Reduced 1.63%
2,948,114 $9.55 Million
Q1 2022

May 16, 2022

BUY
$4.6 - $8.83 $1.21 Million - $2.32 Million
262,811 Added 9.61%
2,996,847 $15.8 Million
Q4 2021

Feb 14, 2022

BUY
$7.75 - $10.05 $10.3 Million - $13.4 Million
1,330,900 Added 94.85%
2,734,036 $23.2 Million
Q3 2021

Nov 15, 2021

BUY
$7.78 - $10.0 $3.75 Million - $4.83 Million
482,631 Added 52.43%
1,403,136 $13.9 Million
Q2 2021

Aug 16, 2021

BUY
$9.22 - $14.48 $8.1 Million - $12.7 Million
878,005 Added 2065.89%
920,505 $8.57 Million
Q1 2021

May 17, 2021

BUY
$9.0 - $14.57 $382,500 - $619,225
42,500 New
42,500 $444,000

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $634M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.